• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

ASO Author Reflections: Sequence of Treatment in Clinically Node-Negative T1 Triple-Negative Breast Cancer.

作者信息

Huang Kai, Jakub James W, McLaughlin Sarah A

机构信息

Breast Surgery, St. Mary Hospital, Prevea Health, Green Bay, WI, USA.

Department of Surgery, Mayo Clinic, Jacksonville, FL, USA.

出版信息

Ann Surg Oncol. 2023 Dec;30(13):8455-8456. doi: 10.1245/s10434-023-14122-x. Epub 2023 Aug 11.

DOI:10.1245/s10434-023-14122-x
PMID:37566286
Abstract
摘要

相似文献

1
ASO Author Reflections: Sequence of Treatment in Clinically Node-Negative T1 Triple-Negative Breast Cancer.ASO作者反思：临床淋巴结阴性T1三阴性乳腺癌的治疗顺序
Ann Surg Oncol. 2023 Dec;30(13):8455-8456. doi: 10.1245/s10434-023-14122-x. Epub 2023 Aug 11.
2
ASO Author Reflections: Sentinel Lymph Node Removal After Neoadjuvant Chemotherapy in Clinically Node-Negative Patients Can Stop After Removal of Three Lymph Nodes.ASO作者反思：临床淋巴结阴性患者新辅助化疗后前哨淋巴结切除在切除三个淋巴结后可停止。
Ann Surg Oncol. 2020 Dec;27(Suppl 3):848-849. doi: 10.1245/s10434-020-08874-z. Epub 2020 Jul 21.
3
ASO Author Reflections: Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy for Node-Positive Breast Cancer: Is It Oncologically Safe?ASO作者反思：新辅助化疗后对淋巴结阳性乳腺癌进行前哨淋巴结手术：从肿瘤学角度看是否安全？
Ann Surg Oncol. 2020 Dec;27(Suppl 3):707-708. doi: 10.1245/s10434-020-08954-0. Epub 2020 Jul 31.
4
ASO Author Reflections: Low Rates of Axillary Recurrence in Clinically Node-Positive Breast Cancer Patients Undergoing Sentinel Lymph Node Biopsy Alone Following Pathologic Response to Neoadjuvant Chemotherapy.ASO作者反思：新辅助化疗病理反应后仅接受前哨淋巴结活检的临床淋巴结阳性乳腺癌患者腋窝复发率低
Ann Surg Oncol. 2021 May;28(5):2630-2631. doi: 10.1245/s10434-020-09259-y. Epub 2020 Oct 29.
5
ASO Author Reflections: Avoiding an Axillary Lymph Node Dissection: The Benefit of Neoadjuvant Chemotherapy for Occult Primary Breast Cancer.美国骨科学会作者反思：避免腋窝淋巴结清扫术：新辅助化疗对隐匿性原发性乳腺癌的益处。
Ann Surg Oncol. 2020 Dec;27(Suppl 3):865-866. doi: 10.1245/s10434-020-08939-z. Epub 2020 Jul 28.
6
ASO Author Reflections: Exploring Discordant Response to Neoadjuvant Therapy in Breast Cancer: Insights into the Clinical and Biological Implications of Persistent Lymph Node Metastasis.
Ann Surg Oncol. 2023 Dec;30(13):8464-8465. doi: 10.1245/s10434-023-14398-z. Epub 2023 Oct 11.
7
ASO Author Reflections: Do We Need to Clip Metastatic Lymph Nodes at Diagnosis and Localize Them After Neoadjuvant Chemotherapy?
Ann Surg Oncol. 2022 Oct;29(10):6140-6141. doi: 10.1245/s10434-022-12405-3. Epub 2022 Aug 11.
8
ASO Author Reflections: Neoadjuvant Systemic Therapy and Nodal Management in cT1-2 N0 Triple-Negative Breast Cancer.ASO作者反思：cT1-2 N0三阴性乳腺癌的新辅助全身治疗与淋巴结管理
Ann Surg Oncol. 2024 May;31(5):3196-3197. doi: 10.1245/s10434-024-15020-6. Epub 2024 Feb 10.
9
ASO Author Reflections: Axillary Staging in Node-Positive Breast Cancer Patients Treated with Neoadjuvant Chemotherapy-Beyond Clinical Trials.ASO作者反思：新辅助化疗治疗的淋巴结阳性乳腺癌患者的腋窝分期——超越临床试验
Ann Surg Oncol. 2020 Oct;27(11):4523-4524. doi: 10.1245/s10434-020-08693-2. Epub 2020 Jun 4.
10
ASO Author Reflections: Positive Sentinel Lymph Node in Breast Cancer Surgery.《美国外科医师学会（ASO）作者反思：乳腺癌手术中前哨淋巴结阳性》
Ann Surg Oncol. 2022 Feb;29(2):1096-1097. doi: 10.1245/s10434-021-10836-y. Epub 2021 Sep 24.

引用本文的文献

1
Recent Advances in RNA Interference-Based Therapy for Hepatocellular Carcinoma: Emphasis on siRNA.基于 RNA 干扰的肝细胞癌治疗的最新进展：重点是 siRNA。
Cell Biochem Biophys. 2024 Sep;82(3):1947-1964. doi: 10.1007/s12013-024-01395-6. Epub 2024 Jul 10.

本文引用的文献

1
The role of tumor-infiltrating lymphocytes in triple-negative breast cancer and the research progress of adoptive cell therapy.肿瘤浸润淋巴细胞在三阴性乳腺癌中的作用和过继细胞治疗的研究进展。
Front Immunol. 2023 May 18;14:1194020. doi: 10.3389/fimmu.2023.1194020. eCollection 2023.
2
Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer.c-TRAK TN 试验结果：一项利用 ctDNA 突变追踪来检测中高危早期三阴性乳腺癌患者分子残留疾病并触发干预的临床试验。
Ann Oncol. 2023 Feb;34(2):200-211. doi: 10.1016/j.annonc.2022.11.005. Epub 2022 Nov 22.
3
Imaging features of breast cancer molecular subtypes: state of the art.
乳腺癌分子亚型的影像学特征：最新进展
J Pathol Transl Med. 2021 Jan;55(1):16-25. doi: 10.4132/jptm.2020.09.03. Epub 2020 Nov 9.
4
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.乳腺癌的病理完全缓解和长期临床获益：CTNeoBC 汇总分析。
Lancet. 2014 Jul 12;384(9938):164-72. doi: 10.1016/S0140-6736(13)62422-8. Epub 2014 Feb 14.
5
Favorable prognosis in patients with T1a/T1bN0 triple-negative breast cancers treated with multimodality therapy.多模态治疗治疗 T1a/T1bN0 三阴性乳腺癌患者的预后良好。
Cancer. 2012 Oct 15;118(20):4944-52. doi: 10.1002/cncr.27480. Epub 2012 Mar 5.